On 9 October 2024, NMIN spin-off company SeraGene Therapeutics was awarded the $3000 “Coup de Coeur” prize at Sweet Pharma Day, one of only two prizes awarded.
At the event, which took place in Sainte-Julie, Quebec, 16 companies, pre-selected by the organizing committee and Pharma representatives, were given 15 minutes each to showcase their innovations to a prestigious audience of industry leaders and investors.
Dr. Erika Siren, Chief Executive Officer, presented on behalf of SeraGene.
“Erika was the last to present on the day and she did a great job, evidently appreciated by everyone in the room,” comments NMIN Board Director Dr. Inès Holzbaur, who attended as Founder and Managing Partner of AmorChem, an event sponsor.
Left: Dr. Erika Siren (CEO, SeraGene) and Dr. Inès Holzbaur (AmorChem). Bottom right: Dr. Siren is presented with a portion of her prize by a representative of CQIB.
The event’s top prize, the $5000 Best Presentation Sweet 16 Award, was awarded to Neuropeutics Inc.
SeraGene Therapeutics is a pre-clinical stage biotech company committed to reimagining the treatment of coagulation disorders through innovative RNA and nanomedicine technologies. It was co-founded by NMIN research leader Dr. Christian Kastrup.
Sweet Biopharma Day is a Quebec-based networking event providing executives from young Canadian biotech companies with the opportunity to directly interact with international pharmaceutical companies and key venture capital firms to develop synergistic partnerships. It is organized by adMare BioInnovations, AmorChem, IOQuébec, CQDM, and Fonds de solidarité FTQ. The “sweet” theme refers to the sugar maple trees that proliferate in Quebec, including around the venues where the event is held.